A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

Trial Profile

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2015

At a glance

  • Drugs Abiraterone acetate (Primary) ; Degarelix (Primary) ; Dutasteride (Primary) ; Enzalutamide (Primary) ; Prednisolone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 24 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top